Search results
11 mar 2023 · Radical treatments (prostatectomy or radiotherapy) reduced the incidence of metastasis, local progression, and long-term androgen-deprivation therapy by half as compared with active monitoring.
- Perspective Access to Biomedical Innovation — Inside The Legal Labyrinth A.K. Rai
Pierre-Henri Duée, Sophie Crozier, Florence Jusot,...
- Interactive Medical Case Thinking Outside The Heart R.A. Denu and Others
A 50-year-old woman presented to the ED with pleuritic chest...
- Perspective Toxidrome Recognition and Response G.R. Ciottone, D. Longo, and D. Taichman
In this animated Double Take video from the New England...
- Editorial Genomics in Clinical Practice J.E. Posey and J.R. Lupski
In a remarkable study notable for its scale (>13,500...
- Then and Now O. Sartor
Between 1999 and 2009 in the United Kingdom, 82,429 men...
- Editorial Audio Interview
In this audio interview conducted on April 24, 2023, the...
- Original Article Randomized Trial of BCG Vaccine to Protect Against Covid-19 in Health Care Workers L.F. Pittet and Others
The bacille Calmette–Guérin (BCG) vaccine has...
- Clinical Decisions Dietary Sodium Restriction in Patients With Heart Failure L.L. Chang and Others
This feature about a patient with heart failure offers a...
- Perspective Access to Biomedical Innovation — Inside The Legal Labyrinth A.K. Rai
15 cze 2024 · The PACE-A study is the world’s first randomised trial to compare the long-term side effects of stereotactic body radiotherapy (SBRT) versus surgery in patients with early-stage prostate cancer. People from across the UK who were enrolled on the trial were treated with either SBRT or surgery.
1 paź 2014 · Wprowadzenie. Rak gruczołu krokowego jest jednym z najczęściej występujących nowotworów złośliwych u mężczyzn na świecie. Między innymi, w Stanach Zjednoczonych (25,3:100 000 mężczyzn) każdego roku rozpoznawany jest u ponad 200 000 nowych chorych.
Stereotactic body radiotherapy (SBRT) of 35–36.25 Gy in five fractions with the CyberKnife System yields excellent control with low toxicity in low–intermediate-risk prostate cancer patients. We found no differences in biochemical control and overall survival in relation to dose.
Prostate CanCer treatment As a patient recently diagnosed with localized prostate cancer, it is important that you familiarize yourself with several treatment options. By proactively researching the various approaches to treating your prostate cancer, you’ll be better equipped to arrive at a decision that is best suited for you. We encourage ...
Along with your health, age, and lifestyle, you may be a candidate for Cyberknife if your diagnosis is: Early-stage disease. Localized disease (confined to the prostate). A prostate volume (size) of less than 80-100 cm. A lesion or tumor that is untreatable by surgery or other radiation modalities. Some people with enlarged prostates may be ...
24 lut 2009 · The CyberKnife treatment is indicated for localised cancer prostate in stage cT1/T2a-b N0 M0 with a Gleason score ≤6 and a prostate-specific antigen (PSA) level <10 ng/ml (low risk) or, in selected patients, with a Gleason score of 7 and PSA 10.1–20 ng/ml (intermediate risk).
